Experimental radioactive Hodgkin's therapy shows promise in Phase I trial

Cancer Research UK.jpg

Researchers are encouraged by the results of a small, Phase I experimental trial of a targeted, radioactive monoclonal antibody in patients with relapsed or refractory Hodgkin's lymphoma known as I-CHT25.

The small trial only involved a handful of patients, but according to results published in the journal Clinical Cancer Research, two thirds of patients had complete response to the therapy, in which cancer cells were exposed to radioactive isotopes for as many as four days without ostensible damage to surrounding tissue.

The experimental therapy appears to function similarly to Bexxar and Zevalin.

The study was backed by Cancer Research UK's Experimental Cancer Medicine Centre at University College London, and development of a Phase II trial for I-CHT25 is underway.

By Ross Bonander

LymphomaInfo Social